Citi Upgrades Arcturus Therapeutics to Buy Following Positive Trial Data
Citigroup upgraded its rating for Arcturus Therapeutics (ARCT) from Neutral to Buy following positive mid-stage trial results for ARCT-810, an experimental treatment targeting ornithine transcarbamylase deficiency. The messenger RNA medicines company reported encouraging data that has prompted analyst Yigal Nochomovitz at Citi to revise his stance on the stock. The upgrade reflects confidence in Arcturus' progress with its pipeline and potential for future growth, particularly as ARCT-810 advances through clinical development. The move is expected to influence investor sentiment positively toward the biotech firm's prospects in treating rare genetic disorders using mRNA technology.
Tickers: $ARCT
Topics: analyst ratings biotech mRNA therapies